Kinoxis Therapeutics
PrivateLast Round
Grant
Dec 23, 2024
Total Funding Raised
$22.37M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kinoxis Therapeutics operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Grant round in December 2024.
Kinoxis Therapeutics is a biotechnology company developing novel small-molecule therapies for the treatment of neuropsychiatric disorders, including substance use disorders, agitation, and aggression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kinoxis Therapeutics Comparables
Compare Kinoxis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astraea Therapeutics | 80% | |
| Occentis | 80% | |
| Proniras Corporation | 76% |
For institutional investors. Book with your work email.
Kinoxis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 23, 2024 | ||||
| Series B | Aug 12, 2024 | ||||
| Grant | Jun 8, 2023 | ||||
| VC Round | Dec 22, 2020 | ||||
| Grant | Sep 29, 2019 | ||||
Series A | Feb 15, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kinoxis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute on Drug Abuse | Grant |
| CUREator | Grant |
| NIH RADx | Grant |
| UniSuper Management | Series B |
| Avicella Capital | Series B |
| National Institutes of Health (NIH) | Grant |
| Uniseed | VC Round, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 58% MoM.
- May 16, 2026
Monthly visitors grew 107% MoM, reaching 505.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 4, 2026
Kinoxis Therapeutics attends the World Congress on Pain in Nov '26 and reports data with the University of Sydney on KNX-100 and KNX-101 for chronic neuropathic pain.
- receives_financingSep 23, 2026
In Australia in Sep '26, Kinoxis Therapeutics receives $6.75M in equity funding alongside a $2.5 million Medical Research Future Fund grant, with Main Sequence leading the round and the proceeds supporting clinical trials and treatments for dementia-related agitation and pain.
- is_developingSep 23, 2026
Kinoxis Therapeutics, based in Australia, is developing a treatment for chronic agitation and aggression associated with dementia with $2.5 million in funding after raising $6.75 million in equity.
For institutional investors. Book with your work email.
Kinoxis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Kinoxis Therapeutics's valuation, stock price, and market status.
Is Kinoxis Therapeutics a public or private company?
Kinoxis Therapeutics is a private company.
What is the current stock price of Kinoxis Therapeutics?
Kinoxis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Kinoxis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Kinoxis Therapeutics worth (valuation)?
Valuation information for Kinoxis Therapeutics is not publicly available.
Can I buy Kinoxis Therapeutics stock?
Kinoxis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Kinoxis Therapeutics's last funding round?
Kinoxis Therapeutics's most recent funding round was Grant on December 23, 2024.
Who are the main investors in Kinoxis Therapeutics?
Key investors in Kinoxis Therapeutics include Uniseed.
Will Kinoxis Therapeutics IPO soon?
No public IPO plans have been announced for Kinoxis Therapeutics.
How can I track Kinoxis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Kinoxis Therapeutics's shares on secondary markets.